Last reviewed · How we verify
Low dose combination polydiuretic therapy
A fixed-dose combination of multiple diuretics at reduced individual doses that work synergistically to reduce blood pressure and fluid retention while minimizing electrolyte disturbances.
A fixed-dose combination of multiple diuretics at reduced individual doses that work synergistically to reduce blood pressure and fluid retention while minimizing electrolyte disturbances. Used for Hypertension management, Fluid overload and edema reduction.
At a glance
| Generic name | Low dose combination polydiuretic therapy |
|---|---|
| Also known as | Eplerenone (inspra), Bumetanide (Burinex) and Empagliflozin (jardiance) |
| Sponsor | The George Institute |
| Drug class | Diuretic combination |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Low-dose combination polydiuretic therapy typically combines agents from different diuretic classes (such as thiazides, potassium-sparing diuretics, and loop diuretics) at sub-therapeutic individual doses. By using lower doses of multiple agents with complementary mechanisms, the approach aims to achieve additive blood pressure reduction while reducing adverse effects like hypokalemia and metabolic derangements that occur at higher single-agent doses.
Approved indications
- Hypertension management
- Fluid overload and edema reduction
Common side effects
- Hypokalemia
- Hyperuricemia
- Hyperglycemia
- Electrolyte imbalance
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: